February 2, 2016
BC Platforms, a world leader in genomic data management solutions, today announced that it has signed a contract with Nexus Personalized Health Technologies to create a joint translational research driven offering connecting genetic and clinical information to enable new innovative patient centric solutions in healthcare. Nexus is a leading provider of services to biomedical researchers in bioinformatic and biostatistical data analysis and will facilitate data integration among different technology-enabling groups of ETH Zurich and hospitals generating clinical data.
Tero Silvola, CEO of BC Platforms commented: “Together Nexus and BC Platforms have the capabilities to provide powerful healthcare solutions to our partners. We now have the tools and technologies for the interpretation of complex proprietary genomic data in combination with publicly available clinical data through local initiatives in Switzerland and internationally.”
Dr Daniel Stekhoven, Head of the Clinical Bioinformatics Unit within Nexus at ETH Zurich commented: “Nexus is committed to integrating genomic data alongside clinical data to become a leader in translational research in order to provide the best clinical outcomes for patients. We are pleased to be working with BC Platforms, a leader in genomic software management systems, to provide joint solutions to tackle current genomic data challenges and practically link those to clinical benefits.”
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and information technologies. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize drug development and clinical decision-making to bring personalized medicines to patients.
Our management team consists of industry leaders with over 90 years of combined experience in life sciences, computational biology and industrial technology. We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. BC Platforms has global operations with its research and development located in Helsinki, Finland, and sales and marketing based in Basel, London, Boston, and Vancouver.
Nexus is a newly-established ETH Technology Platform with two closely integrated units – Clinical Bioinformatics (CB) and Theragnostics Discovery (TD) – that develop and offer technologies for the analysis of multidimensional genomic data and their integration with medical information and provide robotic systems, genome-scale gene manipulation tools, chemical compound collections and advanced cell systems to discover and interfere with disease-causing cell circuits.